10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

10x Genomics (TXG) reported robust Q2 2025 financial results, with revenue reaching $172.91 million, a 12.9% year-over-year increase and a 24% beat against consensus estimates. The company also achieved positive EPS of $0.28, a significant improvement from -$0.32 in the prior year and a 180% surprise over analyst expectations. While consumables and services revenue exceeded estimates, instrument sales notably declined by 39.2% year-over-year. TXG shares have recently outperformed the S&P 500 and hold a Zacks Rank #2 (Buy), indicating potential near-term market outperformance.

Analysis

10x Genomics (TXG) presented a Q2 2025 report with exceptionally strong headline figures that mask significant underlying weaknesses in key business segments. The company reported revenue of $172.91 million, a 12.9% year-over-year increase that surpassed consensus estimates by a notable 24%. Even more striking was the swing to profitability, with EPS of $0.28 decisively beating the consensus forecast of a -$0.35 loss and reversing the -$0.32 loss from the prior-year quarter. However, a detailed segment analysis reveals a concerning trend. Instrument revenue, a critical indicator of future consumable sales, plummeted 39.2% year-over-year to $14.5 million, also falling short of analyst estimates. Furthermore, the core consumables business, while beating muted expectations at $122.19 million, contracted by 1% year-over-year, challenging the narrative of a robust recurring revenue stream. The sole area of strong growth was the much smaller services segment, which expanded 43.9% YoY. The market has so far responded to the positive headline surprises, with the stock's +4.6% return in the past month outperforming the S&P 500.

Key Decisions for Investors

• Investors should scrutinize the drivers behind the significant EPS beat, as the underlying weakness in core instrument and consumables revenue suggests profitability may not be sustainable from sales growth alone.
• The 39.2% year-over-year decline in instrument sales is a major red flag for future growth; monitor management's commentary for explanations on this decline and its impact on the long-term sales funnel for high-margin consumables.
• While the stock has near-term positive momentum indicated by its Zacks Rank #2 and recent outperformance, the conflicting signals between headline beats and deteriorating core segment sales warrant a cautious approach before establishing or adding to a long-term position.